← Back to patent-cliff list
LY-3938577
Tier C — Watch / tradeLY-3938577
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：INSR
Indications (approved)：Type 2 diabetes, Type 1 diabetes
Regional status
US
Phase II
2025-10-13
EU
Phase I
2024-05-15
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-3938577?
Approved indications include: Type 2 diabetes, Type 1 diabetes.
When does the LY-3938577 patent expire?
No public expiry year is available for LY-3938577 yet; this page updates once verified.
How do I get a quote for LY-3938577 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30